ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1624

Prognostic Value of Baseline 18F-FDG PET/CT Scan in Giant Cell Arteritis with Large Vessel Involvement

Julio Sánchez-Martín1, Javier Loricera2, Isabel Martinez-Rodriguez3, ivan Ferraz-Amaro4, Nestor Martinez-Amador5, Remedios Quirce-Pisano5, Fernando Lopez-Gutierrez6 and Ricardo Blanco-Alonso7, 1Hospital Universitario 12 de Octubre, Madrid, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Nuclear Medicine, Hospital Universitario Marques de Valdecilla,IDIVAL, Santander, Cantabria, Spain, 4Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 5Department of Nuclear Medicine, Hospital Universitario Marqués de Valdecilla, Molecular Imaging Group, IDIVAL, Santander., Santander, Spain, 6Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 7Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

Meeting: ACR Convergence 2024

Keywords: giant cell arteritis, Nuclear Medicine, prognostic factors, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan has become a very useful diagnostic tool in patients with GCA with large vessel involvement. However, there are few studies on the prognostic utility of 18F-FDG PET/CT scan in these patients.

Our aim was to assess whether the assessment of baseline 18F-FDG uptake is able to predict the outcome of patients with GCA with large vessel involvement.

Methods: Study of patients diagnosed with GCA with large vessel involvement in a referral hospital who have a baseline 18F-FDG PET/CT scan and a control 18F-FDG PET/CT scan in the following 2 years. Patients were divided into two groups: a) favourable evolution (clinical improvement, normalisation of CRP and ESR and improvement on control 18F-FDG PET/CT scan); and b) unfavourable evolution (no clinical improvement or no normalisation of CRP and ESR or no improvement on control 18F-FDG PET/CT scan). The assessment of 18F-FDG uptake was performed using the Meller visual scale.

Results: We present 20 patients (13 females and 7 males) with a mean age of 68.0±8.6 years with GCA with large vessel involvement who had a baseline and a follow-up 18F-FDG PET/CT scan in the following 2 years (mean time between both 18F-FDG PET/CT scans: 13.6±3.9 months) . Five patients (25%) experienced a favourable outcome, while 15 (75%) patients experienced an unfavourable outcome. No significant differences were observed in the baseline characteristics of the two groups, although there was a greater tendency to present hypertension and dyslipidaemia, as well as to use lower doses of prednisone in the group of patients with unfavourable evolution (TABLE). Patients with favourable outcome had higher baseline 18F-FDG uptake in supra-aortic trunks (2 [1-3] vs 1 [0-1]; p=0. 042), abdominal aorta (2 [1-2] vs 0 [0-1]; p=0.029), iliac arteries (1 [1-1] vs 0 [0-0]; p=0.009), and in the total vascular score (7 [7-10] vs 3 [3-4.5]; p=0.013) (FIGURE).

Conclusion: In our series we observed that patients with GCA with large vessel involvement who have a higher 18F-FDG uptake on the Meller visual scale have a more favourable evolution in the two years following diagnosis, possibly helped by the tendency to use a higher dose of prednisone.

Supporting image 1

Supporting image 2


Disclosures: J. Sánchez-Martín: None; J. Loricera: AstraZeneca, 2, 6, Celgene, 2, 6, Eli Lilly, 5, Janssen, 5, Merck/MSD, 2, 5, 6, Novartis, 12, Formation/Congress attendance, Pfizer, 5, Roche, 2, 5, 6, UCB, 2, 5, 6; I. Martinez-Rodriguez: None; i. Ferraz-Amaro: AbbVie/Abbott, 5, 6, Celgene, 6, Janssen, 5, Merck/MSD, 5, 6, Pfizer, 6, Roche, 5, 6, sanofi, 6; N. Martinez-Amador: None; R. Quirce-Pisano: None; F. Lopez-Gutierrez: AstraZeneca, 12, Formation/Congress attendance, 12, Formation/Congress attendance, Novartis, 12, Formation/congress attendance; R. Blanco-Alonso: AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 6, Galapagos, 6, Janssen, 2, 6, Lilly, 2, 6, MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6.

To cite this abstract in AMA style:

Sánchez-Martín J, Loricera J, Martinez-Rodriguez I, Ferraz-Amaro i, Martinez-Amador N, Quirce-Pisano R, Lopez-Gutierrez F, Blanco-Alonso R. Prognostic Value of Baseline 18F-FDG PET/CT Scan in Giant Cell Arteritis with Large Vessel Involvement [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/prognostic-value-of-baseline-18f-fdg-pet-ct-scan-in-giant-cell-arteritis-with-large-vessel-involvement/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prognostic-value-of-baseline-18f-fdg-pet-ct-scan-in-giant-cell-arteritis-with-large-vessel-involvement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology